PledPharma AB Creating value within treatment of life-threatening diseases
|
|
- Asher Johns
- 8 years ago
- Views:
Transcription
1 PledPharma AB Creating value within treatment of life-threatening diseases PledOx : A cure for chemotherapy-induced peripheral neuropathy (CIPN)? Jacques Näsström, PhD, MBA, CEO BIO-Europe 2014 November 3 November 5 Frankfurt, Germany
2 PledPharma is a Swedish pharma company looking to partner PledOx, their lead asset About PledPharma Swedish pharma company with emphasis on oxidative stress and life-threatening diseases Lead compound: PledOx for prevention of severe chemotherapy induced side-effects Projects for other life-threatening diseases in development Clinically established and proven class of compounds Reduced clinical and regulatory risk Favorable patent situation Listed on NASDAQ OMX First North (STO:PLED) 1
3 An estimated 1.7M patients are eligible for platinumand taxane- based chemotherapy in the US, EU5 and JP each year SIZE OF PATIENT POPULATION ADDRESSABLE BY ASSET Thousands of Patients Tumor Incidence 1 # Cycles of Chemotherapy Agents 2 US EU5 JP CRC Pancreatic Breast Lung Ovarian Millions of Cycles 3,5 3 2,5 2 1,5 1 0,5 0 US EU5 JP Oxaliplatin Cisplatin Paclitaxel Carboplatin Docetaxel PledOx is administered per cycle of chemotherapy as a pre-treatment and has demonstrated efficacy in a broad range of tumor types and chemotherapy regimens (PledOx is expected to have efficacy in all tumors/regimens shown above) 1 Sources: SEER, EUCAN, GLOBOCAN 2 Sources: IMS Data on unit sales of chemotherapy agents with regimen assumptions applied; no data for cisplatin in JP 2
4 Many of these patients suffer from a variety of side effects and dose-limiting toxicities Side Effect Neuropathy CIPN Thrombocytopenia Febrile Neutropenia Neutropenia Diarrhea Nausea/ Vomiting Unmet Need Commentary Often have to reduce/discontinue treatment Can have long-term effects Limited treatment options, dose-limiting Treatable with antibiotics, G-CSFs Severity and high cost of complications keep it topof-mind with payers and prescribers G-CSFs can manage, but pre-treatment is restricted to certain patient populations Dose-limiting Can be dose-limiting Used to be major problem, better controlled now High; no current tx options Chemotherapy can be reduced, postponed, or even completely discontinued if severe side effects persist Can lead to suboptimal treatment results Affects quality of life Huge medical need for preventive treatment of chemotherapy induced side-effects Medium; somewhat manageable with current tx options Low; manageable with current tx options 3
5 In particular, neuropathy has no available treatments and lead to treatment modification Current Standard of Care for Neuropathy Management Intervention Commentary TCA, pregabalin and gabapentin None are approved for neuropathy; only manage symptoms Ca-Mg infusion Treatment modification or discontinuation This intervention was formerly commonly used (as much as by 50% of physicians) No longer recommended due to definitive study by Loprinzi et al., ASCO June 2013 About 40% of patients discontinue due to neurotoxicity; negatively affects patient outcomes Source: Gramont et. al. JCO 2000 There is a high unmet need for neuropathy treatment given nothing else is available 4
6 PledOx aims to be a standard pretreatment to chemotherapy treatment PledOx will become a standard addition to prevent severe chemotherapy-induced sideeffects of chemotherapy, including : - Neuropathy - Neutropenia - Thrombocytopenia Huge potential for use with a range of chemotherapies and cancer types More efficacious and broader effect than existing treatments Unique mechanism of action PledPharma goal: maximizing the value of PledOx to patients and shareholders Sources: Leonard et al, BMC Cancer. 2005; 5: 116; American Cancer Society 5
7 PledOx has a unique mechanism of action as a superoxide dismutase mimetic 3000 ESR Spectra Control HX + XO O DMPO Signal intensity Mangafodipir HX + XO O DMPO mangafodipir Signal intensity Magnetic field (G) Magnetic field (G) H 2 O 2 Mitochondrial manganese superoxide dismutases (MnSOD) defend cells against damage due to oxidative stress under normal circumstances Superoxide dismutase mimetics bolster the body s ability to fend off damage due to pathological oxidative stress caused by chemotherapy Manganese-based SOD mimetics like mangafodipir and PledOx act as catalytic antioxidants since manganese can cycle between Mn 2+ ó Mn 3+ - dismutating free-radicals without being consumed These compounds are furthermore potent iron chelators which contribute to their cytotoxic effect on cancer cells Sources: Brurok H, et al. Biochem Biophys Res Commun.1999; Miriyala S et al., Biochimica et Biophysica Acta
8 Clinical development prompted a rational transition of lead compounds from mangafodipir to PledOx MANFOL I study: phase IIa study in colorectal cancer patients: Mangafodipir All further studies: PledOx Clinically proven MRI contrast medium, previously marked but withdrawn due to commercial reasons A low Molecular Enzyme Mimetic (lowmem), MnSOD and iron chelator Strong safety profile (based on >200,000 patients treated with mangafodipir) Rational chemical modification Developed from mangafodipir, but with potential for better efficacy and better safety At equivalent Mn 2+ doses, PledOx was found to be at least 10x more potent than mangafodipir Completed dose-escalation in ongoing Phase IIb trial showed no safety or toxicity issues Pending composition of matter patent until
9 PledOx has a strong preclinical data package demonstrating cytoprotection and anti-tumor activity PledOx protects cells and preserves/enhances the anti-tumoral effect of chemotherapy: PLED compounds are cytotoxic on cancer cells (Fig 7 Karlsson et al. 2012) Manganese containing PLED compounds protect against chemotherapy induced myelosuppression across a range of structurally diverse chemical classes of chemotherapies: taxanes (docetaxel and paclitaxel), pyrimidine analogues (5-FU), anthracyclines (doxorubicin) and platinums (carboplatin and oxaliplatin) (see bolded examples on the bottom right) The anti-tumour activity of the chemotherapy is not compromised but rather potentiated by the PLED compounds (Karlsson et al. 2012, top right graph) W B C 1.2 p = c o n tro ls o x a lip la tin m g /k g c a lm a n g a 6.5 m m o l/k g + o x a l Sources: Alexandre J, et al., Journal of the National Cancer Institute, 2006; Kurz T, et al., Translational Oncology 2012, Laurent A, et al. Cancer Research, 2005, Karlsson JO, et al. Translational Oncology 2012 as well as PledPharma patent applications. 8
10 Pled compound has clinical data demonstrating statistically significant reduction in grade 3/4 AEs MANFOL Clinical Study Design 14 patients with metastatic colorectal cancer Scheduled for 12 treatment cycles with FOLFOX During the first 3 cycles the patients received pretreatment with placebo or the PLED-derivative mangafodipir (18 total placebo cycles, 20 total mangafodipir cycles) Number of adverse events registered according to National Cancer Institute s scale Clinical Study Results Note the lack of grade 3/4 AEs in treated patients 9
11 PledOx is currently in Ph2 PLIANT trial and expects results to read out in Q PledOx Development Program Discovery Pre-clinical Phase I Phase II Regulatory Approval US/ EU Market Launch PLIANT trial: PledOx (calmangafodipir) is being tested in a large international phase IIb study in patients with colorectal cancer treated with chemotherapy FOLFOX Results read out Q Primary endpoint: neutropenia, or reduction in white blood cells (neutrophils) Secondary endpoints include: Peripheral sensory nerve damage (CIPN) Infection due to loss of white blood cells (febrile neutropenia) Recruitment update: All165 patients recruited Results update: Third and final safety analysis after 90 patients passed No grade 2 or worse neuropathy side effects seen within dose escalation population receiving FOFOX with or without addition of bevacizumab 10
12 Promising preliminary data indicates effect with PledOx on CIPN - from unblinded part 1 C IP N P a tie n ts w ith o u t g r a d e 2 o r w o r s e n e u r o p a th y (% ) A ll P le d O x d o s e s c o m b in e d w ith a t le a s t 7 c y F O L F O X (n = 9, 5 w ith b e v a c iz u m a b ) L o p rin z i e t a l J C I C y c le CIPN as rated with the NCI Sanofi oxaliplatin scale # of patients (%) without grade 2 or worse neuropathy Nine out of 11 part 1 patients completed at least 7 cycles with FOLFOX after pre-treatment with PledOx; 2 µmol/kg (n=1), 5 µmol/kg (n=3 all with bevacizumab, 10 µmol/kg (n=5) two with bevacizumab None of these patients displayed any grade 2 or worse neuropathy Comparison with literature data from Loprinzi et al. 2013, JCI
13 PledPharma has a unique and robust IP portfolio Four granted patent families Basic patents in 2017, EP, US and JP Two additional in 2018, EP and US Use of PLED-derivatives as pharmaceuticals for the treatment of oxidative stress related conditions Three patent applications/patents Anticancer effect of certain PLED derivatives, 2028, PCT application in national phase with approved US, Japanese, Chinese, Hong Kong and Russian patent plus a US CIP (continuation in part) Manganese and non-manganese compositions and broad therapeutic use of these new compositions, 2030, PCT application in national phase with approved South African patent Composition of matter, manufacturing process and broad therapeutic use of PledOx, end-2032, PCT Trademarks PledOx registered trademark in EU, US, Switzerland, Australia, Norway and Japan as well as pending in China and Russia 12
14 PledOx represents an attractive licensing opportunity Attribute PledOx Huge commercial opportunity Substantial market size ü Favorable pricing potential High clinical unmet need Strong uptake expected ü Full reimbursement and broad access Strong intellectual property protection through 2032 De-risked safety profile Defined patient population Completely unique MoA in a therapeutic area with limited competition from in-line or pipeline products ü ü ü ü ü 13
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationNew Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationBuilding A Focused Oncology Business
Building A Focused Oncology Business David Meek President, Oncology Our Strategic Priority: To be at the forefront of patient-centric innovation, bringing life-changing cancer therapies to patients with
More informationOut-Patient Chemotherapy for Lung Cancer
Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent
More informationAdditional file 1. Progress of phase II clinical trials of Panagen
Additional file 1. Progress of phase II clinical trials of Panagen Documentation Phase II clinical trial of preparation Panagen was performed in compliance with the following documentation: Approval of
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationNOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Philippe RUSZNIEWSKI
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Réunion APRAMEN, Paris, 2 février 2013 Philippe RUSZNIEWSKI Pôle des Maladies de
More informationREFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market
More informationThe Cancer Patient Journey. Dr. Jaco Fourie
The Cancer Patient Journey Dr. Jaco Fourie The Cancer Patient Journey Prevention and health promotion Screening Diagnosis and staging Treatment Surveillance and survivorship End of life care The Cancer
More informationA Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationDocetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer
Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient
More informationMetastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationUnderstanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org
Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationHow To Use Berberine
Programa Cooperación Farma-Biotech Jornada II: Oncología Novel Berberine derivatives as antitumor agents for cancer Barcelona, 13 de abril de 2011 Programa Cooperación Farma-Biotech Jornada II: Oncología
More informationStrength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
More informationNewsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationCOMPENDIA TRANSPARENCY TRACKING FORM. Sunitinib malate. Metastatic breast cancer, HER2-negative
COMPENDIA TRANPARENCY TRACKING FORM DRUG: unitinib malate INDICATION: Metastatic breast cancer, HER2-negative COMPENDIA TRANPARENCY REQUIREMENT 1 Provide criteria used to evaluate/prioritize the request
More informationGastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/
Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second
More informationOncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care
Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care John Fox, MD MHA Senior Medical Director Priority Health 1 Cancer Care is the Leading Edge of Medical Cost Trend for
More informationTwo-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple
More informationWhat s New With HER2?
What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston
More informationNieuwe ontwikkelingen op het gebied van de angiogeneseremmers
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Emile Voest, MD, PhD Department of Medical Oncology University Medical Center Utrecht the Netherlands 4e Nascholing Targeted Therapy April
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationCLINICAL POLICY Department: Medical Management Document Name: HER2 Breast Cancer Treatments
Page: 1 of 11 Specialist Review: Revised: 06/13 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationCheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated
More informationDNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa
DNB Markets 5 th Annual Health Care Conference, December 0 CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 68 B, 088 Oslo, Norway - www.nordicnanovector.com Forward-looking statements This presentation
More information2014 Onxeo Review and 2015 Perspectives
2014 Onxeo Review and 2015 Perspectives 2014 Consolidated Financial Results - Successful strategic merger and acquisition of Danish company Topotarget giving birth to Onxeo - Products major achievements:.
More informationPrimary Care Management of Colorectal Cancer
Primary Care Management of Colorectal Cancer Dr. Dan Renouf, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Primary Care Management of Colorectal Cancer Survivors Daniel
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationPARP Inhibitors in Lung Cancer. Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center
PARP Inhibitors in Lung Cancer Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center Poly (ADP-ribose) Polymerase (PARP): Mechanism of Action PARPs: family of enzymes that repair
More information[ NASDAQ: MEIP ] Bank of America Merrill Lynch Health Care Conference May 12-14, 2015
[ NASDAQ: MEIP ] Bank of America Merrill Lynch Health Care Conference May 12-14, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements.
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationProgress in Treating Advanced Triple Negative Breast Cancer
Progress in Treating Advanced Triple Negative Breast Cancer Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Triple Negative Breast Cancer by Subtype
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More information(1)Faivre-Finn C, Bouvier AM, Mitry E et al. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed?
Colorectal cancer Chemotherapy for the elderly Dr Christophe TOURNIGAND Hôpital Saint Antoine France Hôpital Charles Lemoyne - Quebec GERCOR EPOG - UPMC Colorectal cancer ( CRC) : an Elderly Disease 3rd
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationMOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies
More informationRecruiting now. Could you help by joining this study?
Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate
More informationCommercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:
More informationRiociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationThe Cell Therapy Catapult
The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing
More informationTrastuzumab (Herceptin ) for patients with metastatic breast cancer
JULY 2007 Incorporates published evidence to November 2006 INFORMATION ABOUT Trastuzumab (Herceptin ) for patients with metastatic breast cancer This information has been developed to help you understand
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationAeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure
11 th Annual Needham Healthcare Conference April 3, 2012 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities
More informationIncorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice
Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice Please see Important Safety Information throughout this presentation and full Prescribing Information available at this 2014 Bayer
More informationLaura Biganzoli Oncologia Medica Nuovo Ospedale di Prato Istituto Toscano Tumori
EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nabpaclitaxel in elderly patients with advanced breast cancer Laura Biganzoli Oncologia Medica
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationThe Brain and Spine CenTer
The Br ain and Spine Center Choosing the right treatment partner is important for patients facing tumors involving the brain, spine or skull base. The Brain and Spine Center at The University of Texas
More informationNon-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationAvastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September
More informationAposense Enhancing Drug Effects
Aposense Enhancing Drug Effects Miri Ben-Ami, M.D. CEO IATI Biomed June 2013 Aposense Proprietary FORWARD LOOKING STATEMENTS The following slides contain forward-looking statements that include, but are
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationHow To Understand The Role Of A Physician Assistant And Nurse In Cancer Care
THE ROLE OF THE PHYSICIAN ASSISTANT AND ADVANCED PRACTICE NURSE IN CANCER CARE Interview with Shannon B. Holloway, MHS, PA-C Ms Holloway is a medical oncology physician assistant and faculty associate
More informationChemotherapy for non-small cell lung cancer
Chemotherapy for non-small cell lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 3. Contents
More informationTricia Cox on 7/18/2012 at Oncology Center. Sarah Randolf. Female
SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationHospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN
Hospital Outpatient Coding and Billing Information Sheet for Neulasta and Neulasta Delivery Kit Neulasta Prefilled Syringe For assistance contact 1-844-MYNEULASTA (1-844-696-3852) or visit www.amgenassistonline.com
More informationHISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS
HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS 1. COMPANY DESCRIPTION Biocad is a Russian full cycle biotechnological company. It deals with development, manufacture and promotion of original
More informationWhat Cancer Patients Need To Know
Taking Part in Clinical Trials What Cancer Patients Need To Know NATIONAL INSTITUTES OF HEALTH National Cancer Institute Generous support for this publication was provided by Novartis Oncology. Taking
More informationWhat is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationOncology Knowledge Bulletin. Strategies in oncology: Spotlight on clinical pathways
Strategies in oncology: Spotlight on clinical pathways 2 In response to rising healthcare costs, US payors have increased efforts to control drug costs, including through step edits or discounts for contracts.
More information